# Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

> **NCT01342757** · NA · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Adult Glioblastoma
- Depression
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** vorinostat
- **DRUG:** temozolomide
- **PROCEDURE:** magnetic resonance spectroscopic imaging
- **OTHER:** survey administration

## Key facts

- **NCT ID:** NCT01342757
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342757, "Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01342757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*